Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression (NCT05630963)
🩺 Plain-English Summary (8th-Grade Level)
This study looks at the role of the Nociceptin/Orphanin FQ receptor system in the brain of individuals with current or past major depressive disorder (MDD). It also examines how individuals with a history of depression make certain decisions and which brain regions are involved in such decisions. Information collected through MRI, PET, biospecimens (i.e., blood, saliva) and behavioral tasks will be used to predict depressive symptoms in the future.
Who can join: Review the eligibility criteria below.
Location: McLean Hospital — Belmont, Massachusetts
Age range: 18 Years to 45 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- McLean Hospital — Belmont, Massachusetts
📞 Contact the Study Coordinator
Phone: (617) 855-4437
Email: mclrew41study@mgb.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Major Depressive Disorder
- Fisher Wallace Neurostimulation & Depression Study — New York, New York
- Study to Assess the Safety and Effectiveness of NMRA-335140-501 — Huntsville, Alabama
- Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD) — Los Angeles, California
- Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin — Toronto, Ontario
- Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder — West Haven, Connecticut
- Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans — West Haven, Connecticut
Explore by condition: All Major Depressive Disorder clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.